Event Report: Cellectis R&D/ Analyst Day

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PARIS--(BUSINESS WIRE)--Regulatory News: Cellectis (Paris:ALCLS) (Alternext: ALCLS.PA), a leader in the development of adoptive immunotherapies based on engineered allogeneic CART cells (UCART) has hosted an R&D/ Analyst Day on September 11 in New York City. This meeting was intended to explain shareholders and investors Cellectis’ research and development. More than 100 people attended that public event at which Cellectis’ scientists provided an overview of the Company's therapeutic innovations with feature presentations by key opinion leaders: Pr. Laurence Cooper, MD Anderson Cancer Center; Dr. Jaume Pons Senior Vice President and CSO of Rinat, the biotech unit of Pfizer and Eric Falcand, Director, Alliance Management & US Licenses at Servier. The meeting started at 8:00 a.m. and ended after a Q&A session at noon.

Help employers find you! Check out all the jobs and post your resume.

Back to news